Recombinant Biotinylated SARS-CoV-2 (COVID-19) S protein (D614G), His,Avitag™, Super stable trimer , 25µg

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 S protein (D614G, R683A, R685A), His,Avitag, Super stable trimer (SPN-C82E3) is the ectodomain of SARS-CoV-2 S protein that contains AA Val 16 - Pro 1213 (Accession # QHD43416.1(D614G)) and D614G mutation, which has become increasingly common in SARS-CoV-2 viruses from around the world .
The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus.
Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
It is the biotinlynated form of SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (MALS verified) (Cat. No. SPN-C52H3).
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 139.7 kDa. The protein migrates as 150-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model"
Díaz, Serrano-Coll, Botero et al
Travel Med Infect Dis (2022)
(2) "Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial"
Mallory, Formica, Pfeiffer et al
Lancet Infect Dis (2022)
(3) "Efficacy of Sinopharm® COVID-19 Vaccine in Hemodialysis Patients: A Preliminary Report"
Alirezaei, Fazeli, Shafiei et al
Iran J Kidney Dis (2022) 16 (4), 259-265
Showing 1-3 of 22551 papers.